ESEric Spierings

Eric Spierings

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric Spierings has a total of 984 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive In Vitro Profiling Demonstrates Successful Immune Evasion of Bioengineered Immune‐Shielded Heart Valves

    by Abraham van Wijk, Leanne Van Den Berg, Isa B. M. Velraeds, Valentina Osorio Zuluaga, Emma T. M. Peereboom, Martijn J. W. E. Rabelink, Arnaud Zaldumbide, Rob C. Hoeben, Marie‐Jose T. H. Goumans, Eric Spierings, et al.

    Living donor valves for valve replacement in pediatric patients, come with the risk of immune rejection of the implanted tissue. To address this, and increase the options for living implants in pediatric patients, we previously developed a lentiviral immune‐shielding strategy that leverages viral immune evasion mechanisms to downregulate surface HLA expression (via US2) and suppress natural killer (NK) cell activation (via Serpin b9). In this study, we comprehensively evaluated the impact of delivery of immune‐shielding genes in donor valve cells and whole donor valves on immune responses in vitro using host peripheral blood mononuclear cells (PBMCs). Our results demonstrate that this approach prevents immune cell‐mediated death of donor heart valve cells and reduces PBMC clustering around the allogeneic valve cells. Transcriptomic analysis of immune‐shielded donor valves via bulk RNA sequencing revealed upregulation of genes associated with immune tolerance pathways commonly observed in viral infections, cancer, and placental development. These findings support the impact of immune‐shielding technology as a strategy to protect allograft heart valves from immune‐mediated degeneration, advancing the path toward durable, immunologically compatible implants for pediatric patients.

  • Open Access

    Recommendations for HLA Genotyping Data Standards and Clinical Laboratory Staffing Considerations

    by Eric Spierings, Nicholas K. Brown, Katy Latham, James Robinson, Mark Melchers, Medhat Askar, Gerald P. Morris, Eric Weimer, Martin Maiers, Abeer Madbouly

    The rapid advances in HLA genotyping technology and the massive amounts of associated data have created a demand for better and more efficient laboratory data management practices. However, while some standards have been developed, there is a need for comprehensive guidelines that include all laboratory data‐related processes such as messaging, storage and retention, documentation, reporting, validation and quality control. An important consideration in developing these recommendations is the feasibility of application in a laboratory setting without posing a substantial staff and cost burden for implementation and long‐term maintenance and the availability of publicly available tools. This article presents evidence‐based recommendations for multiple laboratory general data practices, focusing on HLA genotyping data and associated meta‐data. These recommendations are compiled by experts in the fields of histocompatibility and immunogenetics (H&I) and representation from multiple H&I worldwide professional society leadership with the long‐term goal of adopting these recommendations in future laboratory accreditation requirements.

  • Open Access

    The Phenotype List String Grammar for Enhanced Protein and Antigen Reporting in the Immunogenetic Context

    by Steven J. Mack, Nicholas K. Brown, Loren Gragert, Jan A. Hofmann, William Lemieux, Benedict M. Matern, Kazutoyo Osoegawa, Jürgen Sauter, Martin Maiers, Eric Spierings

    Standardised data representation is fundamental to the integrity, interoperability and reproducibility of immunogenetics and histocompatibility testing. While well‐established standards such as the genotype list (GL) String, histoimmunogenetics markup language (HML) and minimum information for reporting next‐generation sequence genotyping exist for encoding HLA genotyping results, no equivalent syntax currently exists for describing phenotype‐ or antigen‐level information that underlies antibody testing and immunological risk assessment. We introduce the phenotype list (PL) String grammar and the phenotype list string code (PLSC) syntax, structured, machine‐readable grammars designed to represent antigen‐ and protein‐level data across three contexts: (1) the HLA phenotype composition of assay reagents, (2) test results derived from those reagents and (3) clinical interpretations of HLA antibody specificities. PL String extends the hierarchical logic of the GL String grammar, while adapting a subset of GL String delimiters and rules to describe ambiguity, heterodimeric relationships and phenotypic composition. PL String incorporates explicit namespace definitions (e.g., World Health Organization HLA Nomenclature Committee for Factors of the HLA System, Organ Procurement and Transplantation Network, Eurotransplant and NMDP) to ensure traceability and compatibility with existing regulatory and operational frameworks. By harmonising how HLA phenotypic and antibody data are encoded, PL Strings enable automated data exchange between laboratories, registries and information systems, reducing transcription errors and improving computational interpretation. This new grammar establishes a foundation for interoperable representation of serologic and functional HLA data, facilitating reproducible research and enhancing clinical decision support in transplantation and immunogenetics. Technical specifications for PL Strings and PLSCs are available at plstring.org .

  • Open Access

    Maternal–Foetal HLA‐DQB1 Incompatibility Is Associated With Pregnancy‐Induced Hypertensive Disorders in a Genetically Isolated Population

    by Liseanne J. Van’t Hof, Marie‐Louise P. van der Hoorn, Selena Migdis, Geert W. Haasnoot, Emma T. M. Peereboom, Eric Spierings, Pieter J. E. van der Linden, Jacqueline D. H. Anholts, Heleen de Vreede, Winnie Ottenhof, et al.

    In pregnancy, semi‐allogenic foetal trophoblasts express a specific HLA profile mediating maternal leukocyte contact, crucial for placentation. Paradoxically, maternal immunomodulation requires foetal antigen recognition, especially involving certain HLA molecules. Pre‐eclampsia, a severe hypertensive complication, has been linked to antigenic similarity. Previously, we showed no selection for HLA (in)compatibility in uncomplicated naturally conceived pregnancies. However, pre‐eclamptic pregnancies were associated with increased total maternal–foetal HLA and HLA‐C matching. These associations suggest a role for HLA mismatches in immune regulation leading to an uncomplicated pregnancy. To better understand HLA homozygosity in human reproduction, we aimed to determine if there is a preferential selection for HLA compatibility in a genetically isolated population, and its relation to hypertensive complications. A nested case‐control study, comprising 125 uncomplicated pregnancies and 50 with hypertensive complications (29 with pregnancy‐induced hypertension, 21 with pre‐eclampsia) was conducted in a genetically isolated Dutch population (FROH 1.3–3.1). Maternal and foetal HLA‐A, ‐B, ‐C, ‐DRB1, ‐DQA1, ‐DQB1 and maternal killer‐cell immunoglobulin‐like receptor (KIR) genotyping were performed. Maternal–foetal HLA (mis)match counts were compared to expected values from randomisation of paternal HLA haplotypes over maternal haplotypes of the foetuses. Mismatched CD4+ T cell epitopes presented by maternal HLA class II were predicted using the PIRCHE‐II algorithm. In uncomplicated pregnancies, no difference was found between observed and expected maternal–foetal HLA (mis)matches. However, pregnancies with hypertensive complications showed significantly higher observed HLA‐DQB1 mismatches, reflected in PIRCHE‐II scores. No significant differences were found in KIR/HLA‐C frequencies. Interpretation is limited by the small sample size and the grouping of distinct hypertensive disorders. Nonetheless, maternal–foetal HLA‐DQB1 mismatch seems to play a role in the aetiology of hypertensive complications during pregnancy in this population.


  • Open Access

    Molecular Disparity of HY Antigen Affects Chronic Graft-Versus-Host Disease and Relapse in Female-to-Male Stem Cell Transplants

    by Rima M. Saliba, Matthias Niemann, Samer A. Srour, Uri Greenbaum, Kamal K. Alzahrani, Yudith Carmazzi, Gabriela Rondon, Katayoun Rezvani, May Daher, Dan Li, et al.


  • Open Access

    Swine Xenografts Share Few Predicted Indirectly Recognisable SLA‐Derived Epitopes With HLA‐Derived Epitopes From Human Kidney Grafts

    by Benedict M. Matern, Eric Spierings, Emma Peereboom, Matt Tector, Joseph Tector, Massimo Mangiola, Robert A. Montgomery, Matthias Niemann

    Swine‐derived kidneys are a promising alternative organ source for transplantation, but compatibility in the major histocompatibility complex remains an immunological barrier. Furthermore, in repeat transplantations, CD4+ memory T cells can lead to a more rapid immune response against repeated exposure to the same antigens. Several studies have shown that HLA and SLA proteins share overlapping B cell epitopes due to structural or electrostatic similarities, but the role of overlapping T cell epitopes has not been fully explored. This study aims to computationally analyse the potential risk of memory T cell activation in subsequent human‐after‐swine and swine‐after‐human transplantation by evaluating shared T cell epitopes between the two graft sources. We show that while HLA and SLA demonstrate striking structural similarities, their linear protein sequences are very distinct, which translates to disparate HLA‐ and SLA‐derived peptidomes and T cell epitopes. By applying the PIRCHE‐II Tmem analysis to a simulated panel of recipients receiving repeat transplantations from a human kidney and from a swine xenograft, we observed a median of 1 shared T cell epitope in the cross‐species context, compared to a median of 17 shared between two human‐derived kidneys. This suggests that a swine xenograft exposes a low risk of T cell memory against a later human donor, and that xenotransplantation may provide an opportunity to receive a graft for highly HLA‐sensitised recipients.


  • Open Access

    Peptide Sharing Between CMV and Mismatched HLA Class I Peptides Promotes Early T‐Cell‐Mediated Rejection After Kidney Transplantation

    by Emma T. M. Peereboom, Renato de Marco, Kirsten Geneugelijk, Jasvir Jairam, Frans M. Verduyn Lunel, Anna J. Blok, José Medina‐Pestana, Maria Gerbase‐DeLima, Arjan D. van Zuilen, Eric Spierings

    Cytomegalovirus (CMV) infection is related to acute rejection and graft loss after kidney transplantation, though the underlying mechanism remains largely unknown. Some CMV strains produce a peptide that is identical to a peptide sequence found in the leader peptide of specific HLA‐A and ‐C alleles. In this retrospective study of 351 kidney transplantations, we explored whether CMV‐seropositive recipients without the VMAPRTLIL, VMAPRTLLL or VMAPRTLVL HLA class I leader peptide receiving a transplant from a donor with this peptide, faced an increased risk of T‐cell‐mediated rejection (TCMR) in the first 90 days after transplantation. An independent case–control cohort was used for validation (n = 122). The combination of recipient CMV seropositivity with the VMAPRTLIL peptide mismatch was associated with TCMR with a hazard ratio (HR) of 3.06 (p = 0.001) in a multivariable analysis. Similarly, the VMAPRTLLL peptide mismatch was associated with TCMR revealing a HR of 2.61 (p = 0.008). Transplantations featuring either a VMAPRTLIL or a VMAPRTLLL peptide mismatch had a significantly higher cumulative TCMR incidence (p < 0.0001), with the primary impact observed in the first 2 weeks post‐transplantation. The findings could be validated in an independent cohort. Together, our data strongly suggest that CMV‐positive recipients without an HLA peptide identical to a CMV peptide yet transplanted with a donor who does possess this peptide, have a significantly increased risk of early TCMR. Considering the prevention of such an leader peptide mismatch in these patients or adjusting immunosuppression protocols accordingly may hold promise in reducing the incidence of early TCMR.


  • Paternal HLA‐Derived Epitopes and Live Birth in Secondary Recurrent Pregnancy Loss: New Insights From a Clinical Trial

    by Maria Christine Krog, Emma T. M. Peereboom, Kirsten Geneugelijk, Benedict M. Matern, Astrid Marie Kolte, Ole Bjarne Christiansen, Rudi Steffensen, Henriette Svarre Nielsen, Eric Spierings

    Recurrent pregnancy loss (RPL), defined as two or more pregnancy losses before the 24th week of gestation, affects 1%–3% of women worldwide. Approximately, 40% of RPL cases are secondary RPL (sRPL), where women have given birth before facing pregnancy losses. The underlying causes of RPL remain unclear, but immune‐related factors may play a role. Previously, a randomised controlled trial using immunoglobulin (IVIG) in sRPL women with a history of four pregnancy losses performed in our RPL unit did not show significant effects of IVIG treatment overall. Yet, some evidence suggests potential benefits for a subset of sRPL patients. In the cohort used for the randomised controlled trial, we examined the role of maternal HLA class II‐presented fetal HLA‐derived epitopes in sRPL using the predicted indirectly recognisable HLA epitopes (PIRCHE‐II) algorithm. In the placebo group, sRPL mothers with an anti‐HLA antibody response had higher PIRCHE‐II scores when having a live birth compared with sRPL women who experienced another pregnancy loss. This difference was not observed in the IVIG‐treated group. Furthermore, as a proxy for T‐cell memory, the number of overlapping peptides between the two paternal haplotypes in couples having live births without treatment displayed a larger number of overlapping peptides. This effect was primarily driven by class II‐derived peptides. These results suggest that specific combinations of sRPL mothers and fathers, particularly those with an anti‐HLA antibody response, may generate higher PIRCHE‐II scores, which could contribute to successful live births. Understanding these immune interactions may provide insights for personalised diagnostic and therapeutic strategies in sRPL.


  • Open Access

    Histocompatibility

    by Eric Spierings, Alejandro Madrigal, Katharina Fleischhauer

    Human leukocyte antigen (HLA) molecules are the most important histocompatibility antigens, due to their genetic polymorphism and their key role in peptide antigen presentation and T-cell alloreactivity. While full matching for the most relevant HLA loci had been regarded as a prerequisite for successful transplantation until recently, the introduction of posttransplant cyclophosphamide (PTCy) as immune prophylaxis has also allowed successful transplantation across multiple HLA mismatches, thus also enabling access to transplantation for patients without a fully compatible donor. The rules governing high-risk/nonpermissive HLA mismatches, identified in the past as immunopeptidome overlaps, expression levels, and predicted indirectly recognized HLA epitopes (PIRCHEs), will have to be redefined in the PTCy area to further improve patient outcomes.


  • Open Access

    Determination of the clinical relevance of donor epitope‐specific HLA‐antibodies in kidney transplantation

    by Tineke Kardol‐Hoefnagel, Danial Mohammadi Senejohnny, Elena G. Kamburova, Bram W. Wisse, Leon Reteig, Maartje L. Gruijters, Irma Joosten, Wil A. Allebes, Arnold van der Meer, Luuk B. Hilbrands, et al.

    In kidney transplantation, survival rates are still partly impaired due to the deleterious effects of donor specific HLA antibodies (DSA). However, not all luminex‐defined DSA appear to be clinically relevant. Further analysis of DSA recognizing polymorphic amino acid configurations, called eplets or functional epitopes, might improve the discrimination between clinically relevant vs. irrelevant HLA antibodies. To evaluate which donor epitope‐specific HLA antibodies (DESAs) are clinically important in kidney graft survival, relevant and irrelevant DESAs were discerned in a Dutch cohort of 4690 patients using Kaplan–Meier analysis and tested in a cox proportional hazard (CPH) model including nonimmunological variables. Pre‐transplant DESAs were detected in 439 patients (9.4%). The presence of certain clinically relevant DESAs was significantly associated with increased risk on graft loss in deceased donor transplantations (p < 0.0001). The antibodies recognized six epitopes of HLA Class I, 3 of HLA‐DR, and 1 of HLA‐DQ, and most antibodies were directed to HLA‐B (47%). Fifty‐three patients (69.7%) had DESA against one donor epitope (range 1–5). Long‐term graft survival rate in patients with clinically relevant DESA was 32%, rendering DESA a superior parameter to classical DSA (60%). In the CPH model, the hazard ratio (95% CI) of clinically relevant DESAs was 2.45 (1.84–3.25) in deceased donation, and 2.22 (1.25–3.95) in living donation. In conclusion, the developed model shows the deleterious effect of clinically relevant DESAs on graft outcome which outperformed traditional DSA‐based risk analysis on antigen level.